Professional Section Quarterly - Winter 2013 - (Page 12)

73rd Scientific Sessions ■ ■ ■ The Scientific Sessions provides exclusive access to the latest advances in diabetes by world-renowned diabetes experts. Each day’s schedule includes symposia, debates, state-of-the-art lectures, oral and poster presentations, and special lectures and Bruce M. Spiegelman, PhD, addresses. Program content presenting the Banting Lecture is organized into eight proat last year’s Scientific Sessions. gram areas. A preview of planned sessions appears below. (Session titles are subject to change.) ACUTE AND CHRONIC COMPLICATIONS ■ ■ ■ ■ ■ ■ ■ ■ ■ Symposia ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ Small Fiber Dysfunction in the Natural History of Diabetic Neuropathies in Type 1 and Type 2 Diabetes—From the Bench to the Bedside New Insights Into Treatment of Diabetic Retinopathy and Other Complications Novel Insights Into Diabetic Cardiomyopathy Inflammation, Cardiovascular Disease, and Diabetes Managing the Less Common Lipid Disorders The Kidney’s Unholy Triad—Obesity, Hypertension, and Hyperglycemia So Your Patient Has Diabetic Kidney Disease—Now What? Joint ADA/ASN Symposium—From Mice to Men and Back in Diabetic Kidney Disease Osteomyelitis in the Diabetic Foot Oh, My Aching Feet—Painful Diabetic Neuropathy of the Feet Hypoglycemia in Clinical Practice Defective Hypoglycemia Counterregulation in Diabetes Mellitus—Mechanisms, Prevention, and Reversal BEHAVIORAL MEDICINE, CLINICAL NUTRITION, EDUCATION, AND EXERCISE CLINICAL DIABETES/THERAPEUTICS Current Issues ■ ■ ■ ■ ■ ■ ■ ■ ■ Dietary Treatment of Obesity—Are All Calories Alike? ■ Symposia ■ ■ ■ ■ 12 Intensifying Therapy Using Technology and Teams A Brave New World—Self-Management Support in the Community Education Recharged—Diabetes and Technology Diabetes Education—What Matters? Quality Care Measures Can Unfavorably Impact Individual Care Persistent Microalbuminuria as an Adequate Indication of Renin-Angiotensin-Aldosterone System (RAAS) Blocking Therapies In a Patient Who Is Failing Oral Antidiabetic Agent Therapy, the Next Step Is To? Should Sulfonylureas Remain an Acceptable First-Line Add-On Therapy to Metformin? Symposia Current Issues ■ The Spectrum of Gluten-Related Disorders—A Dual Challenge in Diabetes Dietary Sweeteners—Research, Recommendations, and the Real World Mealtime Insulin Dosing—It’s More Than Counting Carbohydrates The Future of Exercise Mimetics—New Insights Into Mechanisms of Exercise Exercise as Adjunct Therapy for Insulin Sensitivity and Diabetes Exercise and Lipid Metabolism Behavioral Interventions for Diabetes—Evidence From Recent Intervention Studies Sleep—A Novel Behavioral Target in Diabetes? What Influences Patients’ Risk Perception and Decision Making for Diabetes Prevention and Control? ADA Education Recognition Program Symposium— Making a Case for Diabetes Education—The Use of a National Diabetes Education Database Behavioral Science Contributions to Understanding Diabetes NDEP Symposium—New Science—Implications for Diabetes Care ■ ■ The Future Is Now—Changing Health Care Delivery Models Maximizing Cost-Effectiveness of Diabetes Prevention and Treatment—Practical Strategies Continuous Glucose Monitoring (CGM) in the Management of Diabetes in Pregnancy Update on Complications in Pregnancy in Women With Pre-Existing Diabetes Applying New Technologies to Advance the Study of Maternal-Infant Outcomes in Obese and Diabetic Women Update on New Insulin Preparations for the Management of Diabetes The Effect of Low Testosterone on Glycemic Control and Health in Diabetes and Obesity Non-Glycemic Effects of Incretin-Based Therapy— Glucagon-Like Peptide-1 (GLP-1) and Dipeptidyl Peptidase-4 (DPP-4) Professional Section Quarterly

Table of Contents for the Digital Edition of Professional Section Quarterly - Winter 2013

Professional Section Quarterly - Winter 2013
Contents
The Guideline Advantage Program
Diabetes Care: Call for Papers
73rd Scientific Sessions News
Research Award Recipients

Professional Section Quarterly - Winter 2013